1. Home
  2. INSM vs ADM Comparison

INSM vs ADM Comparison

Compare INSM & ADM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • ADM
  • Stock Information
  • Founded
  • INSM 1988
  • ADM 1902
  • Country
  • INSM United States
  • ADM United States
  • Employees
  • INSM N/A
  • ADM N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • ADM Packaged Foods
  • Sector
  • INSM Health Care
  • ADM Consumer Staples
  • Exchange
  • INSM Nasdaq
  • ADM Nasdaq
  • Market Cap
  • INSM 26.0B
  • ADM 25.9B
  • IPO Year
  • INSM 2000
  • ADM N/A
  • Fundamental
  • Price
  • INSM $145.10
  • ADM $62.94
  • Analyst Decision
  • INSM Strong Buy
  • ADM Hold
  • Analyst Count
  • INSM 19
  • ADM 6
  • Target Price
  • INSM $142.38
  • ADM $57.17
  • AVG Volume (30 Days)
  • INSM 3.0M
  • ADM 3.5M
  • Earning Date
  • INSM 10-30-2025
  • ADM 11-04-2025
  • Dividend Yield
  • INSM N/A
  • ADM 3.24%
  • EPS Growth
  • INSM N/A
  • ADM N/A
  • EPS
  • INSM N/A
  • ADM 2.28
  • Revenue
  • INSM $398,105,000.00
  • ADM $82,776,000,000.00
  • Revenue This Year
  • INSM $32.47
  • ADM N/A
  • Revenue Next Year
  • INSM $126.03
  • ADM $3.16
  • P/E Ratio
  • INSM N/A
  • ADM $27.66
  • Revenue Growth
  • INSM 21.15
  • ADM N/A
  • 52 Week Low
  • INSM $60.40
  • ADM $40.98
  • 52 Week High
  • INSM $146.84
  • ADM $64.38
  • Technical
  • Relative Strength Index (RSI)
  • INSM 79.86
  • ADM 67.47
  • Support Level
  • INSM $128.02
  • ADM $61.12
  • Resistance Level
  • INSM $146.84
  • ADM $63.06
  • Average True Range (ATR)
  • INSM 3.66
  • ADM 1.18
  • MACD
  • INSM 0.71
  • ADM -0.15
  • Stochastic Oscillator
  • INSM 91.65
  • ADM 73.43

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About ADM Archer-Daniels-Midland Company

Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.

Share on Social Networks: